Skip to content

Neurocrine Biosciences NBIX Cash Flow Statement

Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
$197.9M+28.8%$153.7M-26.6%$209.5M+94.9%$107.5M+1,261%$7.9M-92.3%
$7.2M+12.5%$6.4M-4.5%$6.7M+6.3%$6.3M-4.5%$6.6M+6.5%
$57.2M-2.4%$58.6M+9.1%$53.7M+1.7%$52.8M0.0%$52.8M-20.5%
$145.8M-62.5%$388.4M+70.7%$227.5M+123%$102M+57.4%$64.8M-73.3%
$9.1M$0-100%$13.2M+5.6%$12.5M+16.8%$10.7M+46.6%
-$506.2M-857%-$52.9M+73.1%-$196.7M-578%-$29M-304%$14.2M+121%
$54M$17.7M-88.2%$150M-50.0%
-$86.1M-$3.3M+97.2%-$117.9M+59.3%
-$446.5M-220%$372.8M+389%$76.2M+9.0%$69.9M+280%-$38.9M+66.5%
$136.7M-65.0%$390.8M+82.4%$214.3M+139%$89.5M+65.4%$54.1M-77.0%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Neurocrine Biosciences generate?
Neurocrine Biosciences (NBIX) generated $863.7M in operating cash flow over the trailing twelve months.
What is Neurocrine Biosciences's free cash flow?
After $34.8M of capital expenditures, Neurocrine Biosciences's free cash flow was $831.3M over the trailing twelve months, up 68.9% year over year.
Where does Neurocrine Biosciences's cash flow data come from?
Every line is extracted from Neurocrine Biosciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.